Day: February 3, 2021

Vincit OyjLehdistötiedote 3.2.2021 kello 9:00Vincit Californialle 1,0 miljoonan euron jatkosopimus data-analytiikkaan erikoistuneelta nykyiseltä asiakkaaltaanVincit California on allekirjoittanut yhteistyösopimuksen ohjelmistokehityksen alihankintapalveluista data-analytiikkaan ja tietoturvaan erikoistuneen nykyisen asiakkaansa kanssa. Sopimus koskee vuotta 2021 ja sen arvo on noin 1,0 miljoonaa euroa.Vincit Californian toimitusjohtaja Ville Houttu: “Näin on mukava polkaista käyntiin uusi vuosi. Olemme innoissamme siitä, että saamme olla isossa roolissa tulevaisuuden tietoturva- ja data-analytiikka-teknologian kehityksessä. Pitkäkestoinen sopimus on osoitus tiimin upeasta työstä ja korkeatasoisesta osaamisesta.”Vincit Oyj:n toimitusjohtaja Mikko Kuitunen: “Huomenna tyytyväisemmät asiakkaat ja työntekijät kuin tänään, on Vincitin motto....

Financial report for the period 1 January 2020 to 31 December 2020Sales increased by 4% in Danish kroner and by 7% at CER to DKK 126.9 billion. Sales in International Operations increased by 7% in Danish kroner (10% at CER), and sales in North America Operations increased by 1% in Danish kroner (3% at CER). Sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment.Sales within Diabetes and Obesity care increased by 5% to DKK 108.0 billion (8% at CER), driven by GLP-1 growth of 26% in Danish kroner (29% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Biopharm sales decreased by 1% in Danish kroner (increased by 1% at CER).The R&D pipeline progressed with the submissions of new drug applications for semaglutide 2.4 mg in obesity in the US and the EU. Furthermore, the phase 3b trial with...

Chiffre d’affaires consolidé de 888,1 millions d’euros en 2020en croissance de 3,1% à cours de change courants(+4,8% à cours de change constants*)Le chiffre d’affaires consolidé des filiales opérationnelles de VIEL & Cie atteint 888,1 millions d’euros pour l’année 2020 contre 861,9 millions d’euros sur la même période en 2019, en hausse de 3,1% à cours de change courants.A cours de change constants, le chiffre d’affaires consolidé affiche une hausse de 4,8% pour atteindre 902,8 millions d’euros.Au 4ème trimestre 2020, le chiffre d’affaires consolidé des filiales du Groupe s’élève à 201,4 millions d’euros, en baisse de 3,3% à cours de change courants par rapport à 2019 et en hausse de 2,2% à cours de change constants.La contribution des différents pôles d’activité au chiffre d’affaires consolidé est la suivante :L’activité d’intermédiation...

MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator...

Marseille, Feb. 03, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator...

Marseille, 03 févr. 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui qu’elle organisera une conférence avec des experts sur le rôle potentiel de son candidat médicament expérimental le plus avancé, lacutamab, un anticorps anti-KIR3DL2, en cours de développement dans les lymphomes à cellules T. L’événement virtuel aura lieu le mardi 9 février 2021 à 14h00 CET / 8h00 ET.L’événement comprendra des présentations de l’équipe de management ainsi que des experts suivants :Pierluigi Porcu, Professeur d’oncologie médicale, de dermatologie et de biologie cutanée, Directeur de la division des maladies hématologiques et de transplantation de cellules souches hématopoïétiques de l’Université Thomas Jefferson...

3 February 2021: Borregaard ASA (“Borregaard”, OSE ticker: BRG)At a meeting on 2 February 2021 the Board of Directors of Borregaard ASA decided to propose an ordinary dividend for 2020 of NOK 2.50 per share to the Annual General Meeting. Dividend payment is estimated at NOK 249 million. The exact amount will depend on the number of treasury shares held at the date of the Annual General Meeting. No dividend will be paid on treasury shares held by the Borregaard Group.Provided that the traded shares are subject to ordinary settlement in the Norwegian Securities Register (VPS), shares acquired up to and including 14 April 2021 will carry the right to receive dividends, whereas shares that are acquired on and after 15 April 2021 will not carry the right to receive dividends. Subject to the decision of the Annual General Meeting, the dividend...

SIKA EXTENDS PRODUCT PORTFOLIO FOR SWEDEN’S MINING INDUSTRYSika has further expanded additive production for shotcrete at Spånga, near Stockholm in Sweden, and upscaled to the latest-generation technology. The new process makes it possible to deliver tailored solutions in demanding projects for customers. The primary customer of the set accelerator marketed under the Sigunit® brand is the mining industry, for which a high level of early strength development and maximum safety in shotcrete application is key.Ivo Schädler, Regional Manager EMEA: “The new technology allows us to offer reliable shotcrete solutions that are tailored to customer requirements in the best possible way. Our customers include leading mining companies that sign long-term supply agreements with us. The potential for growth is not limited to Sweden alone,...

Nasdaq CopenhagenLondon Stock ExchangeOther stakeholders3 February 2021Ringkjøbing Landbobank’s annual report for 2020The bank’s board of directors and general management today approved the annual report for 2020.In March 2020 we downwardly adjusted our expectations for net profit for the year as a result of the coronavirus pandemic. During the year we have built up large management reserves for handling of any later impairment charges. However, the bank’s core income was not negatively affected as we had expected in March. We therefore upwardly adjusted our expectations in October. The 2020 profit before tax was realised at the upper end of our expectations.Core earnings2020 – highlightsOur main focus during the coronavirus pandemic has been to help our customers and business partners – and of course to ensure safe working conditions...